Main Logo
+17162654855
[email protected]

Innovation Trends in Global Axial Spondyloarthritis (axSpA) Market: Market Outlook 2026-2034

Global Axial Spondyloarthritis (axSpA) Market by Types (Ankylosing spondylitis (AS), Non-radi), by Drug class (Non-steroidal anti-inflammatory drugs (NSAID), Glucocorticoids, Anti-rheumatic drugs, Others), by North America (United States, Canada, Mexico), by Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), by Asia Pacific (China, Japan, India, Australia, South Korea, Rest of Asia Pacific), by Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), by South America (Brazil, Argentina, Rest of South America) Forecast 2026-2034

Base Year: 2025
234 Pages
Main Logo

Innovation Trends in Global Axial Spondyloarthritis (axSpA) Market: Market Outlook 2026-2034

About Precision Market View

Precision Market View offers precise market research, industry intelligence, and data analysis for healthcare, manufacturing, technology, and energy. Our reports provide the clarity you need to make informed decisions and drive growth.

Our team combines primary research, advanced analytics, and industry expertise to deliver actionable intelligence. We offer syndicated reports, custom research, and consulting services tailored to your business needs.

At Precision Market View, we are committed to quality, transparency, and client satisfaction. Every report is rigorously validated to ensure accuracy and relevance. Our global perspective and local expertise help you understand both the big picture and the finer details of your market.

Stay informed with Precision Market View. Subscribe to our newsletter for the latest updates and research highlights, and follow us on social media for real-time insights.

Precision Market View – Clarity for Your Strategic Decisions.

Geographic Coverage of Global Axial Spondyloarthritis (axSpA) Market

Higher Coverage
Lower Coverage
No Coverage

Global Axial Spondyloarthritis (axSpA) Market REPORT HIGHLIGHTS

AspectsDetails
Study Period 2020-2034
Base Year 2025
Estimated Year 2026
Forecast Period2026-2034
Historical Period2020-2025
Growth RateCAGR of 13.44% from 2020-2034
Segmentation
    • By Types
      • Ankylosing spondylitis (AS)
      • Non-radi
    • By Drug class
      • Non-steroidal anti-inflammatory drugs (NSAID)
      • Glucocorticoids
      • Anti-rheumatic drugs
      • Others
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Table of Contents

  1. 1. Introduction
    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Objective
    • 1.4. Definitions and Assumptions
  2. 2. Executive Summary
    • 2.1. Market Snapshot
  3. 3. Market Dynamics
    • 3.1. Market Drivers
    • 3.2. Market Restrains
    • 3.3. Market Trends
    • 3.4. Market Opportunities
  4. 4. Market Factor Analysis
    • 4.1. Porters Five Forces
      • 4.1.1. Bargaining Power of Suppliers
      • 4.1.2. Bargaining Power of Buyers
      • 4.1.3. Threat of New Entrants
      • 4.1.4. Threat of Substitutes
      • 4.1.5. Competitive Rivalry
    • 4.2. PESTEL analysis
    • 4.3. BCG Analysis
      • 4.3.1. Stars (High Growth, High Market Share)
      • 4.3.2. Cash Cows (Low Growth, High Market Share)
      • 4.3.3. Question Mark (High Growth, Low Market Share)
      • 4.3.4. Dogs (Low Growth, Low Market Share)
    • 4.4. Ansoff Matrix Analysis
    • 4.5. Supply Chain Analysis
    • 4.6. Regulatory Landscape
    • 4.7. Current Market Potential and Opportunity Assessment (TAM–SAM–SOM Framework)
    • 4.8. PMV Analyst Note
  5. 5. Market Analysis, Insights and Forecast 2021-2033
    • 5.1. Market Analysis, Insights and Forecast - by Types
      • 5.1.1. Ankylosing spondylitis (AS)
      • 5.1.2. Non-radi
    • 5.2. Market Analysis, Insights and Forecast - by Drug class
      • 5.2.1. Non-steroidal anti-inflammatory drugs (NSAID)
      • 5.2.2. Glucocorticoids
      • 5.2.3. Anti-rheumatic drugs
      • 5.2.4. Others
    • 5.3. Market Analysis, Insights and Forecast - by Region
      • 5.3.1. North America
      • 5.3.2. Europe
      • 5.3.3. Asia Pacific
      • 5.3.4. Middle East and Africa
      • 5.3.5. South America
  6. 6. Global Axial Spondyloarthritis (axSpA) Market Analysis, Insights and Forecast, 2021-2033
    • 6.1. Market Analysis, Insights and Forecast - by Types
      • 6.1.1. Ankylosing spondylitis (AS)
      • 6.1.2. Non-radi
    • 6.2. Market Analysis, Insights and Forecast - by Drug class
      • 6.2.1. Non-steroidal anti-inflammatory drugs (NSAID)
      • 6.2.2. Glucocorticoids
      • 6.2.3. Anti-rheumatic drugs
      • 6.2.4. Others
  7. 7. North America Global Axial Spondyloarthritis (axSpA) Market Analysis, Insights and Forecast, 2020-2032
    • 7.1. Market Analysis, Insights and Forecast - by Types
      • 7.1.1. Ankylosing spondylitis (AS)
      • 7.1.2. Non-radi
    • 7.2. Market Analysis, Insights and Forecast - by Drug class
      • 7.2.1. Non-steroidal anti-inflammatory drugs (NSAID)
      • 7.2.2. Glucocorticoids
      • 7.2.3. Anti-rheumatic drugs
      • 7.2.4. Others
  8. 8. Europe Global Axial Spondyloarthritis (axSpA) Market Analysis, Insights and Forecast, 2020-2032
    • 8.1. Market Analysis, Insights and Forecast - by Types
      • 8.1.1. Ankylosing spondylitis (AS)
      • 8.1.2. Non-radi
    • 8.2. Market Analysis, Insights and Forecast - by Drug class
      • 8.2.1. Non-steroidal anti-inflammatory drugs (NSAID)
      • 8.2.2. Glucocorticoids
      • 8.2.3. Anti-rheumatic drugs
      • 8.2.4. Others
  9. 9. Asia Pacific Global Axial Spondyloarthritis (axSpA) Market Analysis, Insights and Forecast, 2020-2032
    • 9.1. Market Analysis, Insights and Forecast - by Types
      • 9.1.1. Ankylosing spondylitis (AS)
      • 9.1.2. Non-radi
    • 9.2. Market Analysis, Insights and Forecast - by Drug class
      • 9.2.1. Non-steroidal anti-inflammatory drugs (NSAID)
      • 9.2.2. Glucocorticoids
      • 9.2.3. Anti-rheumatic drugs
      • 9.2.4. Others
  10. 10. Middle East and Africa Global Axial Spondyloarthritis (axSpA) Market Analysis, Insights and Forecast, 2020-2032
    • 10.1. Market Analysis, Insights and Forecast - by Types
      • 10.1.1. Ankylosing spondylitis (AS)
      • 10.1.2. Non-radi
    • 10.2. Market Analysis, Insights and Forecast - by Drug class
      • 10.2.1. Non-steroidal anti-inflammatory drugs (NSAID)
      • 10.2.2. Glucocorticoids
      • 10.2.3. Anti-rheumatic drugs
      • 10.2.4. Others
  11. 11. South America Global Axial Spondyloarthritis (axSpA) Market Analysis, Insights and Forecast, 2020-2032
    • 11.1. Market Analysis, Insights and Forecast - by Types
      • 11.1.1. Ankylosing spondylitis (AS)
      • 11.1.2. Non-radi
    • 11.2. Market Analysis, Insights and Forecast - by Drug class
      • 11.2.1. Non-steroidal anti-inflammatory drugs (NSAID)
      • 11.2.2. Glucocorticoids
      • 11.2.3. Anti-rheumatic drugs
      • 11.2.4. Others
  12. 12. Competitive Analysis
      • 12.1. Company Profiles
        • 12.1.1 Amgen
          • 12.1.1.1. Company Overview
          • 12.1.1.2. Products
          • 12.1.1.3. Company Financials
          • 12.1.1.4. SWOT Analysis
        • 12.1.2 Acelyrin
          • 12.1.2.1. Company Overview
          • 12.1.2.2. Products
          • 12.1.2.3. Company Financials
          • 12.1.2.4. SWOT Analysis
        • 12.1.3 UCB
          • 12.1.3.1. Company Overview
          • 12.1.3.2. Products
          • 12.1.3.3. Company Financials
          • 12.1.3.4. SWOT Analysis
        • 12.1.4 Pfizer*List Not Exhaustive
          • 12.1.4.1. Company Overview
          • 12.1.4.2. Products
          • 12.1.4.3. Company Financials
          • 12.1.4.4. SWOT Analysis
        • 12.1.5 Eli Lilly and Company
          • 12.1.5.1. Company Overview
          • 12.1.5.2. Products
          • 12.1.5.3. Company Financials
          • 12.1.5.4. SWOT Analysis
        • 12.1.6 Johnson and Johnson
          • 12.1.6.1. Company Overview
          • 12.1.6.2. Products
          • 12.1.6.3. Company Financials
          • 12.1.6.4. SWOT Analysis
        • 12.1.7 Kyowa Kirin
          • 12.1.7.1. Company Overview
          • 12.1.7.2. Products
          • 12.1.7.3. Company Financials
          • 12.1.7.4. SWOT Analysis
        • 12.1.8 Novartis Pharmaceuticals Corporation
          • 12.1.8.1. Company Overview
          • 12.1.8.2. Products
          • 12.1.8.3. Company Financials
          • 12.1.8.4. SWOT Analysis
        • 12.1.9 AbbVie
          • 12.1.9.1. Company Overview
          • 12.1.9.2. Products
          • 12.1.9.3. Company Financials
          • 12.1.9.4. SWOT Analysis
      • 12.2. Market Entropy
        • 12.2.1 Company's Key Areas Served
        • 12.2.2 Recent Developments
      • 12.3. Company Market Share Analysis 2025
        • 12.3.1 Top 5 Companies Market Share Analysis
        • 12.3.2 Top 3 Companies Market Share Analysis
    • 12.4. List of Potential Customers
  13. 13. Research Methodology

    List of Figures

    1. Figure 1: Global Global Axial Spondyloarthritis (axSpA) Market Revenue Breakdown (million, %) by Region 2025 & 2033
    2. Figure 2: North America Global Axial Spondyloarthritis (axSpA) Market Revenue (million), by Types 2025 & 2033
    3. Figure 3: North America Global Axial Spondyloarthritis (axSpA) Market Revenue Share (%), by Types 2025 & 2033
    4. Figure 4: North America Global Axial Spondyloarthritis (axSpA) Market Revenue (million), by Drug class 2025 & 2033
    5. Figure 5: North America Global Axial Spondyloarthritis (axSpA) Market Revenue Share (%), by Drug class 2025 & 2033
    6. Figure 6: North America Global Axial Spondyloarthritis (axSpA) Market Revenue (million), by Country 2025 & 2033
    7. Figure 7: North America Global Axial Spondyloarthritis (axSpA) Market Revenue Share (%), by Country 2025 & 2033
    8. Figure 8: Europe Global Axial Spondyloarthritis (axSpA) Market Revenue (million), by Types 2025 & 2033
    9. Figure 9: Europe Global Axial Spondyloarthritis (axSpA) Market Revenue Share (%), by Types 2025 & 2033
    10. Figure 10: Europe Global Axial Spondyloarthritis (axSpA) Market Revenue (million), by Drug class 2025 & 2033
    11. Figure 11: Europe Global Axial Spondyloarthritis (axSpA) Market Revenue Share (%), by Drug class 2025 & 2033
    12. Figure 12: Europe Global Axial Spondyloarthritis (axSpA) Market Revenue (million), by Country 2025 & 2033
    13. Figure 13: Europe Global Axial Spondyloarthritis (axSpA) Market Revenue Share (%), by Country 2025 & 2033
    14. Figure 14: Asia Pacific Global Axial Spondyloarthritis (axSpA) Market Revenue (million), by Types 2025 & 2033
    15. Figure 15: Asia Pacific Global Axial Spondyloarthritis (axSpA) Market Revenue Share (%), by Types 2025 & 2033
    16. Figure 16: Asia Pacific Global Axial Spondyloarthritis (axSpA) Market Revenue (million), by Drug class 2025 & 2033
    17. Figure 17: Asia Pacific Global Axial Spondyloarthritis (axSpA) Market Revenue Share (%), by Drug class 2025 & 2033
    18. Figure 18: Asia Pacific Global Axial Spondyloarthritis (axSpA) Market Revenue (million), by Country 2025 & 2033
    19. Figure 19: Asia Pacific Global Axial Spondyloarthritis (axSpA) Market Revenue Share (%), by Country 2025 & 2033
    20. Figure 20: Middle East and Africa Global Axial Spondyloarthritis (axSpA) Market Revenue (million), by Types 2025 & 2033
    21. Figure 21: Middle East and Africa Global Axial Spondyloarthritis (axSpA) Market Revenue Share (%), by Types 2025 & 2033
    22. Figure 22: Middle East and Africa Global Axial Spondyloarthritis (axSpA) Market Revenue (million), by Drug class 2025 & 2033
    23. Figure 23: Middle East and Africa Global Axial Spondyloarthritis (axSpA) Market Revenue Share (%), by Drug class 2025 & 2033
    24. Figure 24: Middle East and Africa Global Axial Spondyloarthritis (axSpA) Market Revenue (million), by Country 2025 & 2033
    25. Figure 25: Middle East and Africa Global Axial Spondyloarthritis (axSpA) Market Revenue Share (%), by Country 2025 & 2033
    26. Figure 26: South America Global Axial Spondyloarthritis (axSpA) Market Revenue (million), by Types 2025 & 2033
    27. Figure 27: South America Global Axial Spondyloarthritis (axSpA) Market Revenue Share (%), by Types 2025 & 2033
    28. Figure 28: South America Global Axial Spondyloarthritis (axSpA) Market Revenue (million), by Drug class 2025 & 2033
    29. Figure 29: South America Global Axial Spondyloarthritis (axSpA) Market Revenue Share (%), by Drug class 2025 & 2033
    30. Figure 30: South America Global Axial Spondyloarthritis (axSpA) Market Revenue (million), by Country 2025 & 2033
    31. Figure 31: South America Global Axial Spondyloarthritis (axSpA) Market Revenue Share (%), by Country 2025 & 2033

    List of Tables

    1. Table 1: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Types 2020 & 2033
    2. Table 2: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Drug class 2020 & 2033
    3. Table 3: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Region 2020 & 2033
    4. Table 4: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Types 2020 & 2033
    5. Table 5: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Drug class 2020 & 2033
    6. Table 6: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Country 2020 & 2033
    7. Table 7: United States Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    8. Table 8: Canada Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    9. Table 9: Mexico Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    10. Table 10: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Types 2020 & 2033
    11. Table 11: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Drug class 2020 & 2033
    12. Table 12: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Country 2020 & 2033
    13. Table 13: Germany Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    14. Table 14: United Kingdom Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    15. Table 15: France Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    16. Table 16: Italy Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    17. Table 17: Spain Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    18. Table 18: Rest of Europe Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    19. Table 19: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Types 2020 & 2033
    20. Table 20: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Drug class 2020 & 2033
    21. Table 21: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Country 2020 & 2033
    22. Table 22: China Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    23. Table 23: Japan Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    24. Table 24: India Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    25. Table 25: Australia Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    26. Table 26: South Korea Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    27. Table 27: Rest of Asia Pacific Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    28. Table 28: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Types 2020 & 2033
    29. Table 29: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Drug class 2020 & 2033
    30. Table 30: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Country 2020 & 2033
    31. Table 31: GCC Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    32. Table 32: South Africa Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    33. Table 33: Rest of Middle East and Africa Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    34. Table 34: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Types 2020 & 2033
    35. Table 35: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Drug class 2020 & 2033
    36. Table 36: Global Axial Spondyloarthritis (axSpA) Market Revenue million Forecast, by Country 2020 & 2033
    37. Table 37: Brazil Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    38. Table 38: Argentina Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033
    39. Table 39: Rest of South America Global Axial Spondyloarthritis (axSpA) Market Revenue (million) Forecast, by Application 2020 & 2033

    Frequently Asked Questions

    1. What is the projected Compound Annual Growth Rate (CAGR) of the Global Axial Spondyloarthritis (axSpA) Market?

    The projected CAGR is approximately 13.44%.

    2. Which companies are prominent players in the Global Axial Spondyloarthritis (axSpA) Market?

    Key companies in the market include Amgen, Acelyrin, UCB, Pfizer*List Not Exhaustive, Eli Lilly and Company, Johnson and Johnson, Kyowa Kirin, Novartis Pharmaceuticals Corporation, AbbVie.

    3. What are the main segments of the Global Axial Spondyloarthritis (axSpA) Market?

    The market segments include Types, Drug class.

    4. Can you provide details about the market size?

    The market size is estimated to be USD 1873.8 million as of 2022.

    5. What are some drivers contributing to market growth?

    Improvements in awareness and increasing patient pool; Advancements of biologica and New therapeutic options in the pipeline.

    6. What are the notable trends driving market growth?

    The Non-steroidal Anti Inflammatory Drug Class Segment is Expected to Hold a Major Market Share in the Studied Period.

    7. Are there any restraints impacting market growth?

    Delayed Diagnosis and High cost involved in treatment.

    8. Can you provide examples of recent developments in the market?

    In April 2022, Ampersand Health and UCB announced a partnership to help patients with Axial Spondyloarthritis (axSpA). The two companies will be supporting Project Nightingale, an ongoing study run by the Royal National Hospital for Rheumatic Diseases (RNHRD) in Bath. The project is designed to assist axSpA patients in managing their symptoms and improving their quality of life.

    9. What pricing options are available for accessing the report?

    Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.

    10. Is the market size provided in terms of value or volume?

    The market size is provided in terms of value, measured in million.

    11. Are there any specific market keywords associated with the report?

    Yes, the market keyword associated with the report is "Global Axial Spondyloarthritis (axSpA) Market," which aids in identifying and referencing the specific market segment covered.

    12. How do I determine which pricing option suits my needs best?

    The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.

    13. Are there any additional resources or data provided in the Global Axial Spondyloarthritis (axSpA) Market report?

    While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.

    14. How can I stay updated on further developments or reports in the Global Axial Spondyloarthritis (axSpA) Market?

    To stay informed about further developments, trends, and reports in the Global Axial Spondyloarthritis (axSpA) Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.

    Methodology

    Step 1 - Identification of Relevant Samples Size from Population Database

    Step Chart
    Bar Chart
    Method Chart

    Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

    Approach Chart
    Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.

    Note*: In applicable scenarios

    Step 3 - Data Sources

    Primary Research

    • Web Analytics
    • Survey Reports
    • Research Institute
    • Latest Research Reports
    • Opinion Leaders

    Secondary Research

    • Annual Reports
    • White Paper
    • Latest Press Release
    • Industry Association
    • Paid Database
    • Investor Presentations
    Analyst Chart

    Step 4 - Data Triangulation

    Involves using different sources of information in order to increase the validity of a study

    These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.

    Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.

    During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence

    Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.